LT3621960T - Tienopiridinai ir benzotiofenai, naudingi kaip irak4 inhibitoriai - Google Patents
Tienopiridinai ir benzotiofenai, naudingi kaip irak4 inhibitoriaiInfo
- Publication number
- LT3621960T LT3621960T LTEPPCT/US2018/031945T LT18031945T LT3621960T LT 3621960 T LT3621960 T LT 3621960T LT 18031945 T LT18031945 T LT 18031945T LT 3621960 T LT3621960 T LT 3621960T
- Authority
- LT
- Lithuania
- Prior art keywords
- thienopyridines
- benzothiophenes
- useful
- irak4 inhibitors
- irak4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3621960T true LT3621960T (lt) | 2021-10-11 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2018/031945T LT3621960T (lt) | 2017-05-11 | 2018-05-10 | Tienopiridinai ir benzotiofenai, naudingi kaip irak4 inhibitoriai |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10829496B2 (lt) |
| EP (1) | EP3621960B1 (lt) |
| JP (1) | JP7154229B2 (lt) |
| KR (1) | KR102604900B1 (lt) |
| CN (1) | CN110612298B (lt) |
| AR (1) | AR111689A1 (lt) |
| AU (1) | AU2018265130B2 (lt) |
| BR (1) | BR112019023290A2 (lt) |
| CA (1) | CA3062602A1 (lt) |
| CL (1) | CL2019003198A1 (lt) |
| CO (1) | CO2019012494A2 (lt) |
| CY (1) | CY1124552T1 (lt) |
| DK (1) | DK3621960T3 (lt) |
| EA (1) | EA039189B1 (lt) |
| ES (1) | ES2889926T3 (lt) |
| HR (1) | HRP20211583T1 (lt) |
| HU (1) | HUE056493T2 (lt) |
| IL (1) | IL270494B (lt) |
| LT (1) | LT3621960T (lt) |
| MX (1) | MX2019012929A (lt) |
| MY (1) | MY200228A (lt) |
| PE (1) | PE20191817A1 (lt) |
| PL (1) | PL3621960T3 (lt) |
| PT (1) | PT3621960T (lt) |
| RS (1) | RS62430B1 (lt) |
| SI (1) | SI3621960T1 (lt) |
| SM (1) | SMT202100568T1 (lt) |
| TW (1) | TW201900640A (lt) |
| WO (1) | WO2018209012A1 (lt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273432B (en) | 2017-09-22 | 2022-09-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| WO2021011724A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| ES2960521T3 (es) | 2019-07-18 | 2024-03-05 | Bristol Myers Squibb Co | Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4 |
| ES3036306T3 (en) * | 2019-07-23 | 2025-09-17 | Bristol Myers Squibb Co | Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors |
| KR20220044211A (ko) | 2019-08-06 | 2022-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 비시클릭 헤테로시클릭 화합물 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| TW202241891A (zh) | 2020-12-30 | 2022-11-01 | 美商凱麥拉醫療公司 | Irak降解劑及其用途 |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| AR127505A1 (es) | 2021-10-29 | 2024-01-31 | Kymera Therapeutics Inc | Degradadores irak-4 y síntesis de los mismos |
| WO2023147594A2 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| EP1399440B1 (en) | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| AU2003244098A1 (en) | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
| DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| EP1651636A1 (en) | 2003-07-10 | 2006-05-03 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| AR053158A1 (es) | 2005-03-09 | 2007-04-25 | Schering Corp | Compuestos para inhibir la actividad de quinesina de ksp |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| RU2471793C2 (ru) | 2007-06-08 | 2013-01-10 | Байер Кропсайенс Аг | Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| US20110230467A1 (en) | 2008-11-21 | 2011-09-22 | Astellas Pharma Inc. | 4,6-diaminonicotinamide compound |
| JP5542692B2 (ja) | 2008-11-28 | 2014-07-09 | 興和株式会社 | ピリジン−３−カルボキシアミド誘導体 |
| WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| ES2444777T3 (es) | 2009-06-12 | 2014-02-26 | Bristol-Myers Squibb Company | Compuestos de nicotinamida útiles como moduladores de quinasas |
| CA2772625A1 (en) | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| BR112012010220A2 (pt) | 2009-10-30 | 2021-02-23 | Janssen Pharmaceutical N.V. | piridinas fenóxi-substituídas como modulares do receptor opioide |
| WO2011093501A1 (ja) | 2010-02-01 | 2011-08-04 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
| CA2834045A1 (en) | 2011-04-29 | 2012-11-01 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| WO2013106612A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| TW201427953A (zh) | 2012-11-08 | 2014-07-16 | 必治妥美雅史谷比公司 | 可作爲激酶調節劑之經雜芳基取代的吡啶化合物 |
| ES2616812T3 (es) | 2012-11-08 | 2017-06-14 | Bristol-Myers Squibb Company | Compuestos piridilo sustituidos con heterociclo bicíclico útiles como moduladores de quinasa |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| RS58597B1 (sr) | 2014-04-04 | 2019-05-31 | Pfizer | Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora |
| US10155765B2 (en) * | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| EP3268003B1 (en) | 2015-03-12 | 2020-07-29 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| UY36747A (es) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen |
| CN107849039B (zh) | 2015-06-24 | 2020-07-03 | 百时美施贵宝公司 | 经杂芳基取代的氨基吡啶化合物 |
| ES2865199T3 (es) | 2015-08-27 | 2021-10-15 | Pfizer | Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4 |
-
2018
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 MY MYPI2019006520A patent/MY200228A/en unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en not_active Ceased
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 SM SM20210568T patent/SMT202100568T1/it unknown
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active Active
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
-
2019
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3621960T (lt) | Tienopiridinai ir benzotiofenai, naudingi kaip irak4 inhibitoriai | |
| ZA201905811B (en) | Novel inhibitors | |
| PL3718370T3 (pl) | Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity | |
| IL269711A (en) | ASK1 inhibitory compounds and their uses | |
| EP3268003A4 (en) | Thienopyrazine inhibitors of irak4 activity | |
| EP3283488A4 (en) | Heterocycles useful as ido and tdo inhibitors | |
| SG11202003790PA (en) | Composition and method | |
| IL263949A (en) | Complement inhibitors and their uses | |
| ZA201907136B (en) | Ip6k inhibitors | |
| LT3621694T (lt) | Lrrc33 inhibitoriai ir jų panaudojimas | |
| IL274425A (en) | Pyrrolopyrazine derivatives as alpha five integrin inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL264785B (en) | History of concentrated thiophenes useful as napi-iib inhibitors | |
| EP3704104A4 (en) | IRAK4 INHIBITORS AND THEIR USES | |
| IL275935A (en) | Its use and its derivative | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| IL281216A (en) | Inhibitors of glutaminyl cyclase | |
| PT3725791T (pt) | Sal que serve como inibidor de akt e seu cristal | |
| ZA201904187B (en) | Method and composition | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK40024434A (en) | Thienopyridines and benzothiophenes useful as irak4 inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| HK40017044A (en) | Benzothiophene and benzothiazole compounds and methods of use thereof | |
| GB201714238D0 (en) | Composition and method |